Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 18/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569124 | 0.88 | GSK3B (0.45) | ADORA2AADORA1USP2ALDH1A1CYP1A2 | |
| SCHEMBL14569129 | 0.82 | ADORA2A (0.44) | ADORA2AADORA1USP2ALDH1A1CYP1A2 | |
| SCHEMBL4512221 | 0.82 | ADORA2A (0.63) | ADORA2AADORA1USP2ALDH1A1CYP1A2 | |
| SCHEMBL5332245 | 0.81 | ADORA2A (0.69) | ADORA2AADORA1 | |
| SCHEMBL14569112 | 0.80 | ADORA2A (0.54) | ADORA2AADORA1USP2ALDH1A1CYP1A2 | |
| SCHEMBL4525961 | 0.80 | ADORA2A (0.81) | ADORA2AADORA1 | |
| SCHEMBL13966183 | 0.80 | ADORA2A (0.67) | ADORA2AADORA1 | |
| SCHEMBL13966117 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1 | |
| SCHEMBL4524130 | 0.78 | ADORA2A (0.69) | ADORA2AADORA1 | |
| SCHEMBL5153092 | 0.78 | ADORA2A (0.47) | ADORA2AADORA1USP2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | ADORA2A, P2RX6, P2RX5 | ADORA2A 1/4885ADORA1 9/4885USP2 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.